Ass Sportive Du Ctre Alexis Vautrin
- Address
- lock Available on a paid plan
Neoplasms Research at Ass Sportive Du Ctre Alexis Vautrin
The Oncologie department at Ass Sportive Du Ctre Alexis Vautrin is conducting clinical research in Neoplasms, with a focus on improving care for patients with aggressive gynecologic cancers. The studies explore both new treatment strategies and ways to better identify which patients are most likely to benefit from additional therapy.
- Endometrial cancer in patients with MMR deficiency, including advanced and metastatic disease
- Uterine leiomyosarcoma after surgery, especially localized, resected cases with a higher risk of relapse
- Testing whether adding immunotherapy or chemotherapy can improve disease control and survival outcomes
This research aims to compare treatment approaches, strengthen relapse-free survival and progression-free survival, and support more personalized decisions for patients treated at the site.
Gynecologic Oncology Trials in France
In Vandoeuvre Les Nancy, the site is also contributing to studies that refine postoperative management for high-risk uterine leiomyosarcoma. These trials are designed to evaluate whether extra treatment after surgery can reduce the chance of recurrence in patients identified as higher risk by tumor-based testing.
- Localized, resected uterine leiomyosarcoma with suspected high relapse risk
- Post-operative chemotherapy versus observation after surgery
- Assessing whether treatment can extend the time before cancer returns
The research combines oncology and molecular risk assessment to help determine when additional therapy may be worthwhile and when standard follow-up may be sufficient.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ass Sportive Du Ctre Alexis Vautrin
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Doxorubicin and Trabectedin Chemotherapy in High-Risk Localized Resected Uterine Leiomyosarcoma | Unicancer | Phase II | Recruiting | Jan 2025 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 1 | Unknown | 2022-04-15 | 2022-04-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.